Abuse Deterrent Immediate Release Egg-Shaped Tablet (Egglets) Using 3D Printing Technology: Quality by Design to Optimize Drug Release and Extraction
Opioid abuse is a growing problem and has become a national health crisis over the past decade in the USA. Oral ingestion, snorting, and injection are the most commonly employed routes of abuse for an immediate release product. To circumvent these issues, we have developed an egg-shaped tablet (egglet) using fused deposition modeling (FDM) 3D printing technology. Drug-loaded polymeric filaments (1.5 mm) were prepared using hot melt extrusion (HME) followed by printing into egglets of different sizes and infill densities. Based on printability and crush resistance, polyvinyl alcohol (PVA) was found to be the most suitable polymer for the preparation of abuse deterrent egglets. Further, egglets were evaluated and optimized for mechanical manipulation using household equipment, milling, particle size distribution, solvent extraction, and drug release as per the FDA guidance (November 2017). A multifactorial design was used to optimize egglets for solvent extraction and drug release. Extreme hardness (> 500 N) and very large particle size (> 1 mm) on mechanical manipulation confirmed the snorting deterring property while less than 15% drug extraction in 5 min (% Sext) demonstrated the deterrence for injection abuse. Quality target product profile D85 < 30 min and % Sext < 15 was achieved with egglets of 6 mm diameter, 45% infill density, and 15% w/w drug loading. Dose of drug can be easily customized by varying dimension and infill density without altering the composition. HME coupled with FDM 3D printing could be a promising tool in the preparation of patient-tailored, immediate release abuse deterrent formulation.
KEY WORDS3D printing technology abuse deterrent dosage form quality by design dose customization hot melt extrusion
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no competing interests.
- 5.Nalamachu SR, Shah B. Abuse of immediate-release opioids and current approaches to reduce misuse, abuse, and diversion. Postgrad Med. 2018:1–7.Google Scholar
- 7.Food U, Administration D. Guidance for industry: abuse-deterrent opioids–evaluation and labeling. Silver Spring: US Department of Health and Human Services; 2015.Google Scholar
- 8.Food U, Administration D. Guidance for industry: general principles for evaluating the abuse deterrence of generic solid oral opioid drug products. Silver Spring: US Department of Health and Human Services; 2016.Google Scholar
- 13.Peacock A, Larance B, Bruno R, Pearson SA, Buckley NA, Farrell M, et al. Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting. Addiction. 2018.Google Scholar
- 15.Khan MF, Gharibo C. Abuse deterrent opioids. Tech Reg Anesth Pain Manag. 2010;14(2):99–103.Google Scholar
- 16.Marnoor SA. Abuse deterrent opioid formulations: a review. Res J Pharm Dosage Forms Technol. 2016;8(2):135.Google Scholar
- 17.Boyce H, Smith D, Byrn S, Saluja B, Qu W, Gurvich VJ, et al. In vitro assessment of nasal insufflation of comminuted drug products designed as abuse deterrent using the vertical diffusion cell. AAPS PharmSciTech. 2018:1–14.Google Scholar
- 23.Beaumont J, Cassidy TA, Oyedele N, Guenther S, Mickle TC. Characterizing abuse progression of immediate-release hydrocodone combination products. J Drug Issues. 2018:0022042618756691.Google Scholar
- 30.Martinez PR, Goyanes A, Basit AW, Gaisford S. Influence of geometry on the drug release profiles of stereolithographic (SLA) 3D-printed tablets. AAPS PharmSciTech:1–7.Google Scholar
- 31.Administration UFD. Center for drug evaluation and research. Application number: 200534Orig1s000. Clinical pharmacology and biopharmaceutics review (s). 2010.Google Scholar
- 33.Laboratories R. RIOMET (metformin hydrochloride) [package insert]. Jacksonville: Ranbaxy Laboratories Inc; 2017.Google Scholar
- 34.Pharma P. OXYCONTIN® (oxycodone hydrochloride) [package insert]. Stamford: Purdue Pharma L.P.; 2007.Google Scholar
- 35.Palekar S, Nukala PK, Mishra SM, Kipping T, Patel K. Application of 3D printing technology and quality by design approach for development of age-appropriate pediatric formulation of baclofen. Int J Pharm. 2018.Google Scholar
- 36.Patki M, Patel K. Development of a solid supersaturated self-nanoemulsifying preconcentrate (S-superSNEP) of fenofibrate using dimethylacetamide and a novel co-processed excipient. Drug Dev Ind Pharm. 2018;(just-accepted):1–44.Google Scholar
- 38.Hajare AA, Patil VA. Formulation and characterization of metformin hydrochloride floating tablets. Asian J Pharm Res. 2012;2(3):111–7.Google Scholar
- 39.Corporation EM. Tech Info Parteck MXP_EN_MSIG 2016 [Available from: http://www.emdmillipore.com/US/en/products/small-molecule-pharmaceuticals/formulation/solid-dosage-form/parteck-excipients/parteck-mxp/Ieyb.qB.lAcAAAFYLEQeWww_,nav. Accessed 11 Jan 2018.
- 41.2016. Available from: http://www.emdmillipore.com/US/en/product/Parteck-SI-150-Sorbitol,MDA_CHEM-103583. Accessed 11 Jan 2018.
- 43.Cailly-Dufestel V, Herry C, Bacon J, Oury P, Inventors; Google Patents, assignee. Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion 2010.Google Scholar
- 45.Bartholomäus J, Schwier S, Brett M, Stahlberg H, Galia E, Strothmann K. New abuse deterrent formulation (ADF) technology for immediate-release opioids. Drug Dev Deliv. 2013;13(8):76–81.Google Scholar
- 46.Food U, Administration D. Center for drug evaluation and research. Application number: 206162Orig1s000. Clinical pharmacology and biopharmaceutics review (s). 2014.Google Scholar
- 47.Kumar V, Dixon D, Tewari D, Wadgaonkar DB, inventors; Google Patents, assignee. Extended release opioid abuse deterrent compositions and methods of making same 2012.Google Scholar